Illinois Municipal Retirement Fund trimmed its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 10.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,909 shares of the company’s stock after selling 16,545 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Roivant Sciences were worth $5,226,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in shares of Roivant Sciences by 179.0% during the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after acquiring an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. bought a new stake in shares of Roivant Sciences in the first quarter worth $45,066,000. Assenagon Asset Management S.A. grew its stake in shares of Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after purchasing an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Roivant Sciences by 64.7% in the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock worth $77,560,000 after purchasing an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Roivant Sciences in the third quarter worth $35,624,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Roivant Sciences
In related news, CEO Eric Venker sold 187,943 shares of the business’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $40.53, for a total value of $7,617,329.79. Following the transaction, the chief executive officer owned 811,211 shares in the company, valued at $32,878,381.83. The trade was a 18.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Pulik sold 175,000 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $41.85, for a total transaction of $7,323,750.00. Following the sale, the chief financial officer directly owned 222,046 shares in the company, valued at $9,292,625.10. This trade represents a 44.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,982,747 shares of company stock worth $74,398,784 over the last three months. 8.80% of the stock is owned by company insiders.
Roivant Sciences Stock Performance
Shares of NASDAQ ROIV opened at $39.53 on Monday. The company has a market capitalization of $28.55 billion, a P/E ratio of -62.75 and a beta of 1.23. Roivant Sciences Ltd. has a 52-week low of $19.96 and a 52-week high of $42.50. The company’s 50 day moving average price is $37.31 and its 200-day moving average price is $32.25.
Latest Roivant Sciences News
Investors following ROIV have been watching these news items:
- Positive Sentiment: HC Wainwright raised its price target to $48 and maintained a Buy rating. Other recent commentary has pointed to Roivant’s pipeline momentum and possible contributions from clinical progress and drug-launch revenue. HC Wainwright price-target report Pipeline momentum analysis
- Neutral Sentiment: A separate article examines how trial outcomes and drug-launch revenue could affect ROIV, but the provided headline does not report new trial results or specific revenue figures. Trial and drug-launch analysis
- Negative Sentiment: CEO Eric Venker sold 187,943 shares, reducing his stake by 18.81%; the sale was made under a pre-arranged Rule 10b5-1 plan. CFO Richard Pulik sold 125,000 shares on Nov. 10 and another 175,000 on Nov. 11, cutting his position by 44.08%. These substantial insider sales may create near-term pressure on the stock, although the CEO’s transaction was scheduled in advance. CEO SEC filing CFO insider-sales report
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on ROIV shares. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Finally, Guggenheim increased their price target on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $46.64.
Get Our Latest Research Report on ROIV
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
Further Reading
- Five stocks we like better than Roivant Sciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
